• Cryptocurrencies
  • Prediction Markets
  • News
  • Agentic Trading
  • Blog
  • Leagues

Search Cryptocurrencies

Trending Cryptocurrencies

CoinRithm

Company

Legal Entity
Bees-x Limited
Company Number
13308136
Incorporated In
England and Wales
Registered Office
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm is an information and research service operated by Bees-x Limited. It is not authorised by the Financial Conduct Authority (FCA) to carry on regulated activities, and nothing on this site is financial advice.

Explore

CryptocurrenciesPrediction MarketsNewsBlogAgent ArenaLeagues

Features

DashboardMock TradeAgentic TradingPortfolioWatchlistSettings

Company

About UsMethodologyFor ClassroomsTerms of UsePrivacy PolicyCookie PolicyDisclaimer

Support

Contact SupportFAQDeveloper kitMCP docs

Socials

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. All rights reserved.
Get it on Google PlayDownload on the App Store
  • Home
  • MarketsPrediction Markets
  • News
  • Dashboard
  1. Prediction Markets
  2. China
  3. FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)

FDA decision: Ivonescimab by Summit Therapeutics (in 2026)

ChinaOne-OffHealth & Medicine6mo
KalshiKalshiCheck availabilityKYC required2% fee
Current implied probability
Yes
Yes 0%
Market quality

24 / 100

Low quality
24h Volume

$0

Liquidity

$0

Low liquidity
Bid / Ask

54.0% / 62.0%

Spread

14.8%

Wide spread
Market data

Updated 1 minute ago

Jun 17, 26, 9:00 PMJan 1, 27, 4:59 AM

Trends

Outcome24hChance
Yes
Yes
0%
No
No
100%

Selected outcome

Yes0%

Rules

If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time.
  • It was developed by Akeso and is being commercialized outside China by Summit Therapeutics.
  • By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time.

Related Markets

Manifold Markets

Will China have more phase 3 drug trials than the United States in year X?

$425
2026: 33%Manifold MarketsMANIFOLD MARKETS
Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

$44.3K
Yes: 4%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

$6.8K
Yes: 11%PolymarketPOLYMARKET
Measles cases in U.S. by June 30?

Measles cases in U.S. by June 30?

$2.5K
2150: 41%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

$1.5K
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

$1.1K
Yes: 22.2%Manifold MarketsMANIFOLD MARKETS

Active in these topics

BitcoinBTC$64,730.41-1.43%EthereumETH$1,761.64-1.33%SolanaSOL$72.51-1.28%DogecoinDOGE$0.0864-0.93%XRPXRP$1.19-1.79%BNBBNB$603.80-0.04%

Related News

Chinese Man Gets 10+ Years for Stealing 107 BTC Using Memorized KeyBlockchain.NewsPentagon adds Alibaba, Baidu and BYD to China’s military-linked list Crypto NewsNvidia’s CEO declines Senate testimony on China’s AI chip businessCrypto NewsChina warns developers over overseas AI relay servicesCrypto NewsChina court treats Bitcoin as property in 107 BTC theft caseCrypto NewsChinese court treats Bitcoin as property in 107 BTC memory theft caseCointelegraph

Rules

If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time.
  • It was developed by Akeso and is being commercialized outside China by Summit Therapeutics.
  • By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time.